ALDX
Aldeyra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.36
−1.45%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.38
From 52W high−76.31%
Volume366920.00
Market cap$82.04M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.38
From 52W high
−76.31%
Volume
366920.00
Market cap
$82.04M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
P/E (TTM)
—
RSI (14)
38.2
MomentumView details →
1D Return
−1.45%
YTD Return
−73.75%
SummaryUpdated Jun 1, 2026
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a biotechnology company founded in 2004 and based in Lexington, Massachusetts. Originally incorporated as Aldexa Therapeutics, the company changed its name to Aldeyra Therapeutics in March 2014, coinciding with its initial public offering. The company specializes in developing medicines for immune-mediated ocular and systemic diseases, with a focus on novel therapeutic approaches targeting reactive aldehyde species and other inflammatory pathways.
Similar companies
Latest newsMore news →
Aldeyra Therapeutics, Inc. elected Todd C. Brady, M.D., Ph.D. as a Class III director and appointed Darlene Deptula-Hicks as a Class III director and Chair of the audit committee, effective June 9, 2026.103d agoAldeyra Therapeutics expects near-term FDA feedback on its dry eye disease candidate reproxalap after receiving a third complete response letter.108d ago